TrialPloS one2022

Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.

Alexey V Samtsov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.